NMN and Metabolic Flexibility: How NAD+ Fits In

NMN and Metabolic Flexibility matter because the ability to switch between carbohydrate and fat use helps the body match fuel supply to changing demands. This switching depends on more than calories or exercise alone: it also requires responsive mitochondria, intact insulin signaling, and adequate cellular cofactors. NAD+ is one of those cofactors, and NMN is a compound the body can use in NAD+ metabolism.

The Evidence Base

The human evidence for NMN is still developing. The available studies include small randomized controlled trials, short-term clinical studies, and research in specific groups such as prediabetic women, healthy older men, healthy Japanese men, and amateur runners. These studies provide useful signals, but they do not establish that NMN broadly improves metabolic flexibility in every adult.

The most directly relevant metabolic finding comes from Yoshino et al. (2021). In a randomized controlled trial involving prediabetic women with overweight or obesity, NMN supplementation increased muscle insulin sensitivity. That matters because insulin sensitivity helps muscle take up and use glucose appropriately after meals, a core part of metabolic adaptability.

However, improved insulin sensitivity is not identical to improved metabolic flexibility. Metabolic flexibility is usually assessed by measuring how fuel oxidation changes between fasting and insulin-stimulated states, often with indirect calorimetry or metabolic-clamp methods. The studies provided here do not show that NMN consistently improves every component of that fuel-switching process across populations.

Igarashi et al. (2022) studied chronic NMN supplementation in healthy older men and reported higher blood NAD+ levels along with changes in muscle function. This supports the basic premise that oral NMN can affect NAD+-related biology in humans. It does not prove that raising blood NAD+ automatically produces better glucose control, fat oxidation, or exercise performance for everyone.

Irie et al. (2020) examined oral NMN administration in healthy Japanese men and measured clinical parameters and nicotinamide-related metabolites. The study is important primarily for short-term human tolerability and for showing that NMN can alter circulating nicotinamide metabolite patterns. It was not designed to establish long-term metabolic disease prevention or treatment.

Liao et al. (2021) tested NMN in amateur runners in a randomized, double-blind study and found enhanced aerobic capacity. Aerobic capacity is relevant to metabolic flexibility because endurance work depends heavily on mitochondrial ATP production and the ability to use fuels efficiently. Still, aerobic capacity is not a direct measurement of fasting-to-fed fuel switching, so the result should not be overstated.

Niu et al. (2023) evaluated short-term NMN supplementation during a pre-aging phase and assessed serum metabolism, fecal microbiota, and telomere length. This study expands the discussion beyond blood NAD+ alone by examining broader biological measures. Its findings are preliminary and should be interpreted as exploratory rather than as proof of an anti-aging or metabolic-flexibility effect.

Study	Population	Study type	Primary relevant finding	Relevance to metabolic flexibility
Yoshino et al. (2021)	Prediabetic women with overweight or obesity	Randomized controlled trial	Increased muscle insulin sensitivity	Moderate: insulin responsiveness supports glucose handling
Igarashi et al. (2022)	Healthy older men	Chronic supplementation study	Elevated blood NAD+ and altered muscle function	Moderate: supports NAD+ engagement and muscle relevance
Irie et al. (2020)	Healthy Japanese men	Clinical oral-administration study	Changes in nicotinamide metabolite levels	Limited: useful for human exposure and short-term clinical parameters
Liao et al. (2021)	Amateur runners	Randomized, double-blind study	Enhanced aerobic capacity	Moderate: exercise metabolism is relevant, but flexibility was not directly measured
Niu et al. (2023)	Adults in a pre-aging phase	Short-term supplementation study	Changes assessed in serum metabolism, microbiota, and telomere length	Limited: exploratory and not a direct fuel-switching outcome

What Metabolic Flexibility Actually Means

Metabolic flexibility is the capacity to adjust fuel use according to physiological context. During fasting, lower-intensity movement, and prolonged exercise, the body generally relies more on fatty acids. After a carbohydrate-containing meal or when insulin rises, muscle should be able to increase glucose uptake and oxidation.

This is not an all-or-nothing switch. The body uses carbohydrate and fat simultaneously, but the proportions change. A metabolically flexible person can generally adjust those proportions in response to nutrient availability, energy demand, and hormonal signals.

Reduced flexibility is often discussed alongside insulin resistance and impaired mitochondrial function. When muscle does not respond well to insulin, glucose disposal after meals can be less effective. When mitochondrial capacity is constrained, cells may also have more difficulty matching ATP production to changing fuel availability.

That said, metabolic flexibility is a physiological concept rather than a single diagnostic label. It can be influenced by body composition, sleep, training status, diet composition, recent exercise, age, medications, and the method used to measure it. A supplement study showing one favorable metabolic marker should not be treated as a complete measure of flexibility.

The Mechanism: Where NAD+ Fits In

NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme used throughout energy metabolism. Cells use it to transfer electrons during reactions that help convert carbohydrates, fats, and amino acids into usable energy. NAD+ cycles between its oxidized form, NAD+, and its reduced form, NADH.

In practical terms, NAD+ helps keep metabolic pathways moving. Glycolysis, the tricarboxylic acid cycle, and mitochondrial electron transport all depend on redox reactions involving NAD+/NADH. If this balance is disturbed, cells can have difficulty maintaining efficient energy production.

NAD+ also serves as a substrate for enzyme families involved in cellular signaling and repair. These include sirtuins, PARPs, and CD38-related NAD+-consuming activity. Because these processes use NAD+, cellular NAD+ availability reflects both production and consumption.

NMN, or nicotinamide mononucleotide, is part of the NAD+ salvage pathway. The body can generate NMN from nicotinamide and then use NMN to produce NAD+. Oral NMN supplementation is therefore studied as a way to influence NAD+-related metabolism, rather than as a direct fuel source.

Gomes et al. (2013) provided influential mechanistic evidence in aging models. The study reported that declining NAD+ induced a pseudohypoxic state that disrupted communication between the nucleus and mitochondria. In plain language, the work suggests that lower NAD+ availability may interfere with coordinated mitochondrial regulation during aging.

This finding is biologically important, but it is not a human clinical outcome trial. Animal and cellular mechanisms can help explain why a treatment might work, but they do not determine the size of an effect in people. Human outcomes still need to be measured directly.

NAD+, Mitochondria, and Fuel Selection

Mitochondria are often described as the cell’s energy-producing structures, but their role is more specific than that phrase suggests. They integrate incoming fuel, oxygen availability, ATP demand, and redox state. A well-functioning mitochondrial network helps muscle and other tissues respond to changing energy conditions.

NAD+ is relevant because mitochondrial energy pathways require continuous electron handling. During fat oxidation, for example, multiple reactions generate reducing equivalents that must ultimately be processed by the electron transport chain. During carbohydrate oxidation, NAD+-dependent reactions are also essential.

That does not mean more NAD+ always means more energy or more fat burning. Metabolism is regulated by demand, enzyme activity, oxygen delivery, hormonal status, and nutrient supply. Raising a precursor may be meaningful in a context of reduced NAD+ availability, but the effect may be smaller when baseline metabolic function is already strong.

Why Insulin Sensitivity Is a Key Connection

Insulin sensitivity is one of the clearest links between NMN research and metabolic flexibility. After eating, insulin signals skeletal muscle to take up glucose. If that response is impaired, the transition toward greater carbohydrate use after a meal can be less efficient.

Yoshino et al. (2021) found increased muscle insulin sensitivity in prediabetic women after NMN supplementation. This is a meaningful result because skeletal muscle is a major site of post-meal glucose disposal. It also identifies a group in which NMN may have more measurable metabolic relevance than in young, healthy adults with normal insulin action.

The correct interpretation is narrow: the study supports improved muscle insulin sensitivity in the studied population under the study conditions. It does not show that NMN replaces exercise, dietary changes, weight management, or medical care for prediabetes. It also does not establish that every person with insulin resistance will respond similarly.

What the Research Does Not Show

The current evidence does not establish NMN as a treatment for diabetes, obesity, metabolic syndrome, or age-related disease. None of the provided studies demonstrates that NMN prevents cardiovascular events, reverses diabetes, or produces durable body-fat loss. Those are clinically important outcomes and require larger, longer trials.

It also does not show that NAD+ levels in blood are a complete proxy for NAD+ status in every tissue. Igarashi et al. (2022) reported elevated blood NAD+ in healthy older men, which is useful evidence of biological exposure. But a blood measurement cannot, by itself, prove the same functional change in skeletal muscle, liver, brain, or adipose tissue.

There is also no basis in these studies for assuming that higher doses will necessarily provide larger benefits. Dose-response relationships can differ by population, endpoint, supplement timing, and baseline NAD+ status. More is not automatically better, especially when long-term human data remain limited.

Finally, the evidence base is heterogeneous. The studies use different populations and outcomes, including insulin sensitivity, muscle function, clinical parameters, aerobic capacity, serum metabolism, and microbiota-related measures. That diversity is informative, but it makes broad claims about a single universal NMN effect inappropriate.

Practical Context: Supplements Work Within a Metabolic System

For most people, the largest drivers of metabolic flexibility remain physical activity, aerobic fitness, resistance training, sleep, and overall dietary pattern. Exercise creates repeated demand for ATP and stimulates adaptations in skeletal muscle. Those adaptations are central to how the body handles glucose and fat over time.

NMN should be viewed as a potential adjunct to these fundamentals, not a substitute for them. The runner study by Liao et al. (2021) is especially relevant here: any improvement in aerobic capacity occurred in physically active participants, within a structured exercise context. It does not show that supplementation alone reproduces the metabolic effects of training.

Meal timing and recent activity can also affect how a person experiences energy and glucose regulation. A sedentary day, a night of poor sleep, or a large late meal can influence metabolic responses regardless of supplement use. That is one reason short-term subjective impressions are not a reliable way to judge whether NMN is changing metabolic flexibility.

For consumers choosing an NMN product, the practical questions are simpler than the marketing often suggests: use a clearly labeled form, avoid treating it as medication, and assess it within a consistent routine. A product such as Bio:sudo NMN 1000mg fits into that framework as an NMN option, but its use should not be framed as a guarantee of improved metabolic health.

Who Benefits Most

The strongest human signal in the provided research is in people with reduced metabolic reserve rather than in universally healthy populations. Prediabetic women with overweight or obesity showed improved muscle insulin sensitivity in Yoshino et al. (2021). This suggests that baseline insulin resistance may be an important factor in determining whether NMN produces a measurable metabolic effect.

Healthy older adults are another group of interest. Aging is associated with changes in mitochondrial function, muscle performance, and NAD+-related biology, and Igarashi et al. (2022) showed increased blood NAD+ after chronic supplementation in healthy older men. The study supports further research in this population, while leaving the size and clinical importance of longer-term benefits unresolved.

Endurance-oriented recreational athletes may also be interested because Liao et al. (2021) reported enhanced aerobic capacity in amateur runners. The finding is relevant to exercise performance and mitochondrial energy metabolism. It should not be generalized to strength athletes, sedentary adults, or competitive athletes without additional direct evidence.

Healthy younger adults with no identified metabolic concerns may see less obvious effects. Irie et al. (2020) supports that oral NMN can affect nicotinamide metabolite levels in healthy men, but changes in metabolites do not necessarily translate into a noticeable functional benefit. In people starting from a healthy baseline, the practical value may be uncertain.

People with diabetes, active cancer, pregnancy, breastfeeding, significant kidney or liver disease, or complex medication regimens should not extrapolate from these studies on their own. The provided evidence does not answer important safety and interaction questions for those groups. Clinical guidance is appropriate when there is a medical condition or prescribed treatment involved.

How to Interpret an NMN Routine

It is reasonable to separate measurable outcomes from expectations. Blood NAD+ or nicotinamide metabolite changes are biological markers. Insulin sensitivity, aerobic capacity, muscle function, and longer-term disease outcomes are different endpoints that require their own evidence.

If someone uses NMN, a consistent routine is more informative than frequently changing multiple supplements, diet patterns, and training plans at once. Otherwise, it becomes difficult to attribute any perceived change to NMN. This is especially relevant for people using other supplements, including magnesium glycinate or KSM-66 ashwagandha, because each may be taken for a different purpose.

It is also worth distinguishing performance from metabolic health. Feeling more energetic during a week of training is not the same as demonstrating improved insulin sensitivity. Likewise, a lab marker changing over a short period is not proof of long-term disease-risk reduction.

Bio:sudo NMN 1000mg may be most sensibly considered by adults who understand those limits and want an NMN product within a broader health routine. The available research makes NAD+ biology plausible and shows several human signals worth following. It does not justify promising a predictable metabolic outcome for an individual user.

Practical Takeaways

• Metabolic flexibility describes the ability to shift fuel use with fasting, meals, and activity; it is not measured by a single blood test.
• NAD+ supports redox reactions and mitochondrial energy metabolism, while NMN is a precursor used in NAD+ metabolism.
• Yoshino et al. (2021) found improved muscle insulin sensitivity in prediabetic women, the clearest metabolic outcome among the provided human studies.
• Igarashi et al. (2022) supports that chronic NMN supplementation can elevate blood NAD+ in healthy older men, but blood levels do not prove benefits in every tissue.
• Liao et al. (2021) found enhanced aerobic capacity in amateur runners, but this is not the same as directly demonstrating improved metabolic flexibility.
• Use NMN as an adjunct to training, sleep, and nutrition—not as a replacement for the foundations of metabolic health.

Bottom Line

NMN has a credible biochemical connection to metabolic flexibility because it participates in NAD+ metabolism, and NAD+ is central to cellular energy handling. Human studies show promising but population-specific findings in insulin sensitivity, blood NAD+ levels, muscle-related outcomes, and aerobic capacity. The evidence is encouraging, but it is not yet strong enough to claim that NMN reliably improves metabolic flexibility for everyone.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---